Bio-Technology General deal

Merck Frosst, Canadian subsidiary of Merck & Co., received an exclusive worldwide license to a genetically engineered peptide for thrombus imaging from BTGC's Bio-Cardia Corp. R&D unit. Merck Frosst w...